de Jong Gerdie M, Slager Jasper J, Verbon Annelies, van Hellemond Jaap J, van Genderen Perry J J
Institute for Tropical Diseases, Harbour Hospital, Haringvliet 2, Rotterdam, The Netherlands.
Department of Medical Microbiology and Infectious Diseases, Erasmus MC, Rotterdam, The Netherlands.
Malar J. 2016 Dec 1;15(1):581. doi: 10.1186/s12936-016-1624-8.
Levels of both angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2) correlate with malaria disease severity and are proposed as biomarkers and possible therapeutic targets. To establish their role in malaria, a systematic review was performed of the literature on Ang-1 and Ang-2 with regard to their potential as biomarkers in malaria and discuss their possible place in adjuvant treatment regimens.
Ten electronic databases were systematically searched to identify studies investigating Ang-1 and Ang-2 in human and murine malaria in both clinical and experimental settings. Information about the predictive value of Ang-1 and Ang-2 for disease severity and their regulatory changes in interventional studies were extracted.
Some 579 studies were screened; 26 were included for analysis. In all five studies that determined Ang-1 levels and in all 11 studies that determined Ang-2 in different disease severity states in falciparum malaria, a decline in Ang-1 and an increase of Ang-2 levels was associated with increasing disease severity. All nine studies that determined angiopoietin levels in Plasmodium falciparum patients to study their ability as biomarkers could distinguish between multiple disease severity states; the more the disease severity states differed, the better they could be distinguished. Five studies differentiating malaria survivors from non-survivors with Ang-2 as marker found an AUROC in a range of 0.71-0.83, which performed as well or better than lactate. Prophylactic administration of FTY720, rosiglitazone or inhalation of nitric oxide (NO) during malaria disease in mice resulted in an increase in Ang-1, a decrease in Ang-2 and an increased survival. For rosiglitazone, a decrease in Ang-2/Ang-1 ratio was observed after post-infection treatment in mice and humans with malaria, but for inhalation of NO, an effect on Ang-1 and survival was only observed in mice.
Both Ang-1 and Ang-2 levels correlate with and can distinguish between malaria disease severity states within the group of malaria-infected patients. However, distinct comparisons of disease severity states were made in distinct studies and not all distinctions made had clinical relevance. Changes in levels of Ang-1 and Ang-2 might also reflect treatment effectiveness and are promising therapeutic targets as part of multi-targeted therapy.
血管生成素-1(Ang-1)和血管生成素-2(Ang-2)的水平均与疟疾疾病严重程度相关,被提议作为生物标志物和可能的治疗靶点。为确定它们在疟疾中的作用,对关于Ang-1和Ang-2作为疟疾生物标志物潜力的文献进行了系统综述,并讨论它们在辅助治疗方案中可能的地位。
系统检索了10个电子数据库,以识别在临床和实验环境中研究人类和小鼠疟疾中Ang-1和Ang-2的研究。提取了Ang-1和Ang-2对疾病严重程度的预测价值及其在干预研究中的调节变化的信息。
共筛选了约579项研究;纳入26项进行分析。在所有5项测定恶性疟不同疾病严重程度状态下Ang-1水平的研究以及所有11项测定Ang-2水平的研究中,Ang-1水平下降和Ang-2水平升高与疾病严重程度增加相关。所有9项测定恶性疟患者血管生成素水平以研究其作为生物标志物能力的研究都能区分多种疾病严重程度状态;疾病严重程度状态差异越大,区分效果越好。5项以Ang-2为标志物区分疟疾幸存者和非幸存者的研究发现,受试者工作特征曲线下面积(AUROC)在0.71 - 0.83范围内,其表现与乳酸相当或更好。在小鼠疟疾发病期间预防性给予FTY720、罗格列酮或吸入一氧化氮(NO)导致Ang-1增加、Ang-2减少和存活率提高。对于罗格列酮,在感染疟疾的小鼠和人类感染后治疗后观察到Ang-2/Ang-1比值下降,但对于吸入NO,仅在小鼠中观察到对Ang-1和存活率的影响。
Ang-1和Ang-2水平均与疟疾感染患者组内的疟疾疾病严重程度状态相关且能区分这些状态。然而,在不同研究中对疾病严重程度状态进行了不同的比较,并非所有做出的区分都具有临床相关性。Ang-1和Ang-2水平的变化也可能反映治疗效果,作为多靶点治疗的一部分,它们是很有前景的治疗靶点。